Shopping Cart 0
Cart Subtotal
USD 0

Sinopharm Group Co Ltd (1099) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp is a distributor of pharmaceutical and healthcare products. The group provides distribution, logistics and other value-added services to foreign and domestic manufacturers and suppliers of pharmaceuticals, medical products and supplies and other healthcare products. It also serves hospitals, primary health services institutions and retail drug stores. Sinopharm also manufactures and sells pharmaceuticals, chemical reagents and laboratory supplies, and engages in the innovation of pharmaceutical, medical services and other health-related industries. Besides, the group manages a chain of medicine stores across China through direct operations and franchises to market pharmaceutical and healthcare products. Sinopharm is headquartered in Changning District, Shanghai, China.

Sinopharm Group Co Ltd (1099)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14

Partnerships 15

Chi-Med Forms Joint Venture with Sinopharm 15

Mitsubishi Forms Joint Venture With Sinopharm 16

China NT Pharma To Form Joint Venture With Sinopharm 17

Licensing Agreements 18

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19

Equity Offering 21

Sinopharm Raised USD728 Million in Private Placement of Shares 21

Sinopharm Completes Private Placement Of Shares For USD 525 Million 23

Debt Offering 25

Sinopharm Group Plans Public Offering Of Bonds For USD 633 Million 25

Acquisition 26

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD 132.6 Million 32

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD 6.4 Million 33

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD 2.14 Million 34

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD 5 Million 35

Sinopharm Group Co Ltd-Key Competitors 36

Sinopharm Group Co Ltd-Key Employees 37

Sinopharm Group Co Ltd-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Joint Venture 39

Recent Developments 40

Financial Announcements 40

Jul 31, 2017: Sinopharm Group: Proposed Re-Election And Appointment Of Directors And Supervisors 40

Mar 24, 2017: Sinopharm Group: Annual results announcement for the year ended 31 December 2016 41

Mar 20, 2017: Sinopharm Group: Announcement Preliminary Results of Sinopharm Accord for the Year Ended 31 December 2016 44

Corporate Communications 45

Mar 24, 2017: Sinopharm Group: Change in chairman of the board 45

Other Significant Developments 46

May 31, 2017: Sinopharm Launches New Logo 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14

Chi-Med Forms Joint Venture with Sinopharm 15

Mitsubishi Forms Joint Venture With Sinopharm 16

China NT Pharma To Form Joint Venture With Sinopharm 17

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19

Sinopharm Raised USD728 Million in Private Placement of Shares 21

Sinopharm Completes Private Placement Of Shares For USD 525 Million 23

Sinopharm Group Plans Public Offering Of Bonds For USD 633 Million 25

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD 132.6 Million 32

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD 6.4 Million 33

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD 2.14 Million 34

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD 5 Million 35

Sinopharm Group Co Ltd, Key Competitors 36

Sinopharm Group Co Ltd, Key Employees 37

Sinopharm Group Co Ltd, Subsidiaries 38

Sinopharm Group Co Ltd, Joint Venture 39

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Sinopharm Group Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp is a distributor of pharmaceutical and healthcare products. The group provides distribution, logistics and other value-added services to foreign and domestic manufacturers and suppliers of pharmaceuticals, medical products and supplies and other healthcare products. It also serves hospitals, primary health services institutions and retail drug stores. Sinopharm also manufactures and sells pharmaceuticals, chemical reagents and laboratory supplies, and engages in the innovation of pharmaceutical, medical services and other health-related industries. Besides, the group manages a chain of medicine stores across China through direct operations and franchises to market pharmaceutical and healthcare products. Sinopharm is headquartered in Changning District, Shanghai, China.

Sinopharm Group Co Ltd (1099)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14

Partnerships 15

Chi-Med Forms Joint Venture with Sinopharm 15

Mitsubishi Forms Joint Venture With Sinopharm 16

China NT Pharma To Form Joint Venture With Sinopharm 17

Licensing Agreements 18

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19

Equity Offering 21

Sinopharm Raised USD728 Million in Private Placement of Shares 21

Sinopharm Completes Private Placement Of Shares For USD 525 Million 23

Debt Offering 25

Sinopharm Group Plans Public Offering Of Bonds For USD 633 Million 25

Acquisition 26

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD 132.6 Million 32

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD 6.4 Million 33

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD 2.14 Million 34

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD 5 Million 35

Sinopharm Group Co Ltd-Key Competitors 36

Sinopharm Group Co Ltd-Key Employees 37

Sinopharm Group Co Ltd-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Joint Venture 39

Recent Developments 40

Financial Announcements 40

Jul 31, 2017: Sinopharm Group: Proposed Re-Election And Appointment Of Directors And Supervisors 40

Mar 24, 2017: Sinopharm Group: Annual results announcement for the year ended 31 December 2016 41

Mar 20, 2017: Sinopharm Group: Announcement Preliminary Results of Sinopharm Accord for the Year Ended 31 December 2016 44

Corporate Communications 45

Mar 24, 2017: Sinopharm Group: Change in chairman of the board 45

Other Significant Developments 46

May 31, 2017: Sinopharm Launches New Logo 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47


List Of Figure

List of Figures

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Sinopharm Group Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Sinopharm Group Co Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Sinopharm Group Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 14

Chi-Med Forms Joint Venture with Sinopharm 15

Mitsubishi Forms Joint Venture With Sinopharm 16

China NT Pharma To Form Joint Venture With Sinopharm 17

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 18

Provectus to Enter into Licensing Agreement with Sinopharm-CSIPI and Sinopharm A-THINK for PV-10 19

Sinopharm Raised USD728 Million in Private Placement of Shares 21

Sinopharm Completes Private Placement Of Shares For USD 525 Million 23

Sinopharm Group Plans Public Offering Of Bonds For USD 633 Million 25

China National Accord Medicines Plans to Acquire Remaining 90% Stake in Zhuhai-Based Pharma Firm for USD1.43 Million 26

Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 27

Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 28

Hutchison China MediTech And Sinopharm Acquires 51% Stake In Sinopharm Holding HuYong Pharma For USD9.6 Million 29

Mitsubishi And Medipal Each Acquire 20% Stake In Sinopharm Holding Beijing Tianxingpuxin Bio-Med 31

Sinopharm Group To Acquire 80% Stake In Sinopharm Group Shanxi For USD 132.6 Million 32

Merro Pharma To Sell 42.5% Stake In Shanghai Merro Pharma To Sinopharm For USD 6.4 Million 33

China National Accord To Acquire 70% Stake In Guangdong Pharma Company For USD 2.14 Million 34

China National Accord To Acquire Remaining 25% Stake In Suzhou Zhijun Wanqing Pharma From Yang Qiaoming For USD 5 Million 35

Sinopharm Group Co Ltd, Key Competitors 36

Sinopharm Group Co Ltd, Key Employees 37

Sinopharm Group Co Ltd, Subsidiaries 38

Sinopharm Group Co Ltd, Joint Venture 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Sinopharm Group Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.